Search
Vericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigationalcell types) that catalyze the synthesis of cyclic guanosine monophosphate (cGMP) in response to activation by nitric oxide (NO). … [L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure.
Histidine
go.drugbank.com/drugs/DB00117ApprovedInvestigationalNutraceuticalAn essential amino acid that is required for the production of histamine.
Mixtures: Vamin N, AMINOSTERIL N-HEPA 8%Ceftriaxone
go.drugbank.com/drugs/DB01212ApprovedInvestigationalCeftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. … [A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges[A215582], eyes[A215647], and inner ear[A215627].
Gatifloxacin
go.drugbank.com/drugs/DB01044ApprovedInvestigationalWithdrawnIt works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. … It is also available as eye drops under the brand name Zymar® marketed by Allergan.
Doxorubicin
go.drugbank.com/drugs/DB00997ApprovedInvestigational[A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin … [A257709] Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and
Piperonyl butoxide
go.drugbank.com/drugs/DB09350ApprovedVet approvedIt has no pesticidal activity of its own, but acts to increase the activity of pesticides such as carbamates, pyrethrins, pyrethroids, and rotenone.
Drospirenone
go.drugbank.com/drugs/DB01395ApprovedInvestigationalSome studies have demonstrated a significantly increased risk and some demonstrating no risk of thromboembolic events. … In its statement, the FDA has mentioned that increased risk of venous thromboembolism with oral contraceptives such as drospirenone exists but remains lower than the risk of this condition during pregnancy
Mixtures: Lo-ZumandimineTetrofosmin
go.drugbank.com/drugs/DB11180ApprovedTetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds.
Ancestim
go.drugbank.com/drugs/DB09103ApprovedWithdrawn[T68] It was also approved by Health Canada in 1999 but it is currently under the status of canceled post-market.[L1087] … Ancestim was developed by Amgen and sold to Biovitrium in December 2008. It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes.
Phentolamine
go.drugbank.com/drugs/DB00692ApprovedInvestigationalPhentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. … While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral
Categories: Non-selective Alfa-adrenergic Blocking AgentsSynonyms: 2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline